Paltusotine
Intestinal Neuroendocrine Tumor G1
Explore 1 assets in Intestinal Neuroendocrine Tumor G1 →Floatz Rating
BB66/100
Confidence
Indicative
Sponsor
Crinetics Pharmaceuticals Inc.
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
52Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07087054CT.gov Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen | — | Recruiting | — | — | — |
NCT05361668CT.gov Study to Evaluate the Safety, PK, and Dose Response of Paltusotine in Subjects With Carcinoid Syndrome | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Intestinal Neuroendocrine Tumor G1
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Paltusotine (this asset) | Crinetics Pharmaceuticals Inc. | P3 | BB · 66 |
Other indications for Paltusotine
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Carcinoid Syndrome | — | P3 | BB · 66 |
| Ileal Neuroendocrine Tumor G1 | — | P3 | BB · 66 |
| Cecum Neuroendocrine Tumor G1 | — | P3 | BB · 66 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Citation
Floatz Terminal. Paltusotine in Intestinal Neuroendocrine Tumor G1. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/paltusotine-intestinal-neuroendocrine-tumor-g1
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →